Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?

Overactive Bladder

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Health Qual Life Outcomes.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, Schermer CR

doi: 10.1186/s12955-018-0892-0.

Overactive Bladder

Patient-targeted websites on overactive bladder: What are our patients reading?

Neurourol Urodyn.

Clancy AA, Hickling D, Didomizio L, Sanaee M, Shehata F, Zee R, Khalil H

doi: 10.1002/nau.23359.

Overactive Bladder

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Neurourol Urodyn.

Niederhauser T, Gafner ES, Cantieni T, Grämiger M, Haeberlin A, Obrist D, Burkhard F, Clavica F

doi: 10.1002/nau.23357.

Overactive Bladder

Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial

Urology.

Chen H, Wang F, Yu Z, Zhang Y, Liu C, Dai S, Chen B, Lv J

doi: 10.1016/j.urology.2016.11.008.

Overactive Bladder

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Neurourol Urodyn.

Mueller ER, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Stoelzel M, Yoon SJ, Al-Shukri S, Rechberger T, Gratzke C

doi: 10.1002/nau.23919.

Overactive Bladder

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Patient.

Herdman M, Nazir J, Hakimi Z, Siddiqui E, Huang M, Pavesi M, MacDiarmid S, Drake MJ, Devlin N

doi: 10.1007/s40271-017-0262-8.

Overactive Bladder

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Lupus.

Pereira E Silva R, Romão VC, Neves M, Garcia R, Oliveira S, Brites J, Ramos FO, Canhão H, Palma Dos Reis J, Pereira da Silva JA, Lopes T

doi: 10.1177/0961203318811605.

Overactive BladderUrinary Tract Infections (UTI)

Predictive Factors of De Novo Overactive Bladder after Artificial Urinary Sphincter Implantation in Men with Post-Prostatectomy Incontinence

Urology.

Ko KJ, Lee CU, Kim TH, Suh YS, Lee KS

doi: 10.1016/

Overactive BladderUrinary Tract Infections (UTI)

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes

J Pediatr Urol.

Ingham J, Angotti R, Lewis M, Goyal A

doi: 10.1016/j.jpurol.2018.08.007.

Related content

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)

Patient-targeted websites on overactive bladder: What are our patients reading?

Detection and quantification of overactive bladder activity in patients: Can we make it better and automatic?

Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial

Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study

Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial

Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome

Predictive Factors of De Novo Overactive Bladder after Artificial Urinary Sphincter Implantation in Men with Post-Prostatectomy Incontinence

Onabotulinum toxin A in children with refractory idiopathic overactive bladder: medium-term outcomes